Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Being 70 or older doesn't independently increase the odds of developing immune-related side effects from ipilimumab-nivolumab in metastatic kidney cancer patients, new research finds. But older patients were still more than twice as likely to stop treatment or need steroids due to those side effects. The findings, presented at IKCS: North America 2026, highlight a nuanced risk picture for elderly patients on this standard first-line combo.
Age alone may not predict who develops immune-related adverse events (irAEs) on ipilimumab-nivolumab for metastatic clear cell renal cell carcinoma (mccRCC) — but older patients still face a tougher road when those side effects do occur.
A retrospective analysis of 514 mccRCC patients receiving first-line ipilimumab-nivolumab found that, after adjusting for key clinical factors, being 70 or older was not independently associated with a higher likelihood of developing irAEs overall. That said, older patients experienced notably higher rates of treatment discontinuation and corticosteroid use when irAEs did arise.
By the Numbers:
Why it matters: These findings are clinically important for oncologists managing elderly kidney cancer patients. While age shouldn't be a barrier to receiving this effective combo therapy, clinicians should be prepared for more intensive toxicity management — including earlier steroid intervention and closer monitoring for treatment discontinuation — in patients aged 70 and older.